Rockville, MD (January 12, 2022) - Cellphire Therapeutics, Inc., a biotechnology company developing next-generation allogeneic cellular therapeutics for application across multiple medical indications, announced today the appointment of Roy A. Beveridge, M.D. to the company’s Scientific Advisory Board.
“Roy is a great addition to our Scientific Advisory Board,” said Mike Gaffney, Chief Executive Officer. “His depth of experience and deep insights will help steer us though our next phase of development.”
Dr. Beveridge was previously Chief Medical Officer, McKesson Specialty Health |The US Oncology Network, Executive Vice President/Medical Director and Chairman, Public Policy and Bone Marrow Transplantation, at US Oncology, and Chief Medical Officer at Humana, Inc. He also served as Co-Director of Bone Marrow Transplant Program, INOVA Fairfax Hospital. Dr. Beveridge’s research has focused on oncology, stem cells and cord blood, and he is the author of more than 180 peer reviewed publications in these fields. He is currently Senior Healthcare Advisor at Avalere Health, and a member of the American Society of Hematology. Dr. Beveridge received a Doctor of Medicine from Cornell University and a Bachelor of Arts in cell biology from John Hopkins University.
About Cellphire Therapeutics
Cellphire Therapeutics, Inc. is a biotechnology company developing next-generation allogeneic cellular therapeutics. The company is applying its proprietary cell stabilization technology first to platelets, to develop lifesaving products. Its lead investigational product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technologies support a wide range of potential medical applications from stopping bleeding, healing wounds, and imaging to targeted drug delivery and regenerative medicine. For more information, visit www.cellphire.com.
The Thrombosomes project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201300021.
This (CPP) work is supported by the U.S. Army Medical Research and Development Command under Contract No. W81XWH20C0030.
InvestorRelations and Media
VP, Legal, Strategy & Investor Relations